{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.38","upperLimit":"4.21","value":"2.69"},{"groupId":"OG001","lowerLimit":"1.31","upperLimit":"14.06","value":"8.97"},{"groupId":"OG002","lowerLimit":"1.25","upperLimit":"4.07","value":"2.96"},{"groupId":"OG003","lowerLimit":"2.76","upperLimit":"4.60","value":"4.01"},{"groupId":"OG004","lowerLimit":"1.48","upperLimit":"4.40","value":"2.76"},{"groupId":"OG005","lowerLimit":"2.63","upperLimit":"7.23","value":"3.94"},{"groupId":"OG006","lowerLimit":"1.35","upperLimit":"4.04","value":"2.63"},{"groupId":"OG007","lowerLimit":"1.84","upperLimit":"5.45","value":"3.78"},{"groupId":"OG008","lowerLimit":"3.32","upperLimit":"5.65","value":"3.91"},{"groupId":"OG009","lowerLimit":"2.60","upperLimit":"8.31","value":"3.91"},{"groupId":"OG010","lowerLimit":"1.35","upperLimit":"6.93","value":"1.61"},{"groupId":"OG011","lowerLimit":"1.31","upperLimit":"4.50","value":"2.63"},{"groupId":"OG012","lowerLimit":"1.41","upperLimit":"3.42","value":"2.30"},{"groupId":"OG013","lowerLimit":"2.76","upperLimit":"10.91","value":"5.13"},{"groupId":"OG014","lowerLimit":"3.58","upperLimit":"11.86","value":"4.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"56"},{"groupId":"OG004","value":"57"},{"groupId":"OG005","value":"50"},{"groupId":"OG006","value":"51"},{"groupId":"OG007","value":"61"},{"groupId":"OG008","value":"66"},{"groupId":"OG009","value":"50"},{"groupId":"OG010","value":"49"},{"groupId":"OG011","value":"49"},{"groupId":"OG012","value":"49"},{"groupId":"OG013","value":"36"},{"groupId":"OG014","value":"35"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization date or first dosing date of study medication to the date of the first objectively documented tumor progression or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last tumor assessment.\n\nProgressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks","id":"OG003","title":"Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks","id":"OG004","title":"Cohort 2 Uninfected Sorafenib Progressors: Treatment 2"},{"description":"Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG005","title":"Cohort 2 HCV Infected: Treatment 3"},{"description":"Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG006","title":"Cohort 2 HBV Infected: Treatment 4"},{"description":"Arm A: Advance hepatocellular carcinoma (HCC) participants received nivolumab 240 mg every 2 weeks","id":"OG007","title":"Cohort 3: Treatment 1"},{"description":"Arm B: Advance hepatocellular carcinoma (HCC) participants received Sorafenib 400 mg twice a day","id":"OG008","title":"Cohort 3: Treatment 2"},{"description":"Arm A: Participants received nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks","id":"OG009","title":"Cohort 4: Treatment 1"},{"description":"Arm B: Participants received nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks","id":"OG010","title":"Cohort 4: Treatment 2"},{"description":"Arm C: Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks","id":"OG011","title":"Cohort 4: Treatment 3"},{"description":"Participants received nivolumab 240 mg every 2 weeks","id":"OG012","title":"Cohort 5: Treatment 1"},{"description":"Participants received nivolumab 240 mg every 2 weeks + cabozantinib 40 mg once daily","id":"OG013","title":"Cohort 6: Treatment 1"},{"description":"Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks + cabozantinib 40 mg once daily","id":"OG014","title":"Cohort 6: Treatment 2"}],"paramType":"MEDIAN","populationDescription":"All treated participants for Cohort 1, 2, and 5, and all randomized participants for Cohort 3, 4 and 6. Uninfected HCC, HCV-infected, and HBV-infected participants were pre-specified to be reported together for Cohort 1.","reportingStatus":"POSTED","timeFrame":"From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to documented disease progression or death, whichever occurs first (up to approximately 144 months)","title":"Progression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Months"}